基于二糖核苷的新型组氨酸-DNA-磷酸二酯酶 1 抑制剂类药物原型用于癌症治疗。

Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy.

机构信息

a Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russian Federation.

b Department of Natural Sciences , Novosibirsk State University , Novosibirsk , Russian Federation.

出版信息

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1415-1429. doi: 10.1080/14756366.2018.1509210.

Abstract

A new class of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors based on disaccharide nucleosides was identified. TDP1 plays an essential role in the resistance of cancer cells to currently used antitumour drugs based on Top1 inhibitors such as topotecan and irinotecan. The most effective inhibitors investigated in this study have IC values (half-maximal inhibitory concentration) in 0.4-18.5 µM range and demonstrate relatively low own cytotoxicity along with significant synergistic effect in combination with anti-cancer drug topotecan. Moreover, kinetic parameters of the enzymatic reaction and fluorescence anisotropy were measured using different types of DNA-biosensors to give a sufficient insight into the mechanism of inhibitor's action.

摘要

研究人员基于二糖核苷鉴定出一类新型的酪氨酰 DNA 磷酸二酯酶 1(TDP1)抑制剂。TDP1 在癌细胞对拓扑异构酶 1 抑制剂(如拓扑替康和伊立替康)为基础的现有抗肿瘤药物的耐药性中发挥着重要作用。本研究中研究最深入的抑制剂,其 IC 值(半最大抑制浓度)在 0.4-18.5μM 范围内,并且与抗癌药物拓扑替康联合使用时具有相对较低的自身细胞毒性和显著的协同作用。此外,使用不同类型的 DNA 生物传感器测量了酶反应和荧光各向异性的动力学参数,从而充分了解抑制剂作用的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed12/6136360/f66fe1728f67/IENZ_A_1509210_F0001_C.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索